A phase I study of indoximod in patients with advanced malignancies

PURPOSE: Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum tolerated dose (MTD) and toxicity for indoximod in patients with advanced solid tumors. Secondary endpoints included response rates, pharm...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Soliman, Hatem H., Minton, Susan E., Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A., Roberts, John D., Link, Charles, Vahanian, Nicholas N., Mautino, Mario, Streicher, Howard, Sullivan, Daniel M., Antonia, Scott J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5008412/
https://ncbi.nlm.nih.gov/pubmed/27008709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8216
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky